Immune System Therapeutics Ltd.

Zeposia maintains disease control even in the event of temporary treatment interruption for up to eight weeks Zeposia is the first oral sphingosine 1-phosphate (S1P) receptor modulator approved to treat patients with ulcerative colitis PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced new post hoc analyses from the Phase 3 True North study evaluating the duration of response following continuous Zeposia (ozanimod) treatment for up to one year and following treatment interruption in patients with moderately to severely active ulcerative colitis (UC). After achieving a clinical response at the end of the induction period, 86.1% of patients who remained on Zeposia showed no disease relapse at Week 52 (Kaplan-Meier [KM] estimates of no disease relapse at Week 52: Zeposia / Zeposia , 86.1%; Zeposia /placebo, 62.6%). As temporary treatment discontinuation may occur in clinical practice, these analyses evaluated the duration of response following treatment interruption. Findings showed that Zeposia maintained disease control for up to eight weeks in patients who switched to placebo after initial response (KM estimates of no disease relapse at Week 8: Zeposia / Zeposia , 96.1%; Zeposia /placebo, 90.6%). These analyses (Presentation #62) and 10 additional Zeposia abstracts demonstrating Bristol Myers Squibb’s robust body of research in gastroenterology are being presented at the American College of Gastroenterology (ACG) annual scientific meeting, taking place October 21 – 26, 2022. "Understanding the duration of response after continuous ozanimod treatment is critical, as it can assist in clinical decision making when considering temporary discontinuation of UC treatment in clinical practice," said Bruce E. Sands, MD, MS, Gastroenterologist and paid consultant of Bristol Myers Squibb. Dr. Sands is also the Dr. Burrill B. Crohn Professor of Medicine (Gastroenterology) at the Icahn School of Medicine at Mount Sinai and Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at Mount Sinai Health System. "These analyses reaffirm that ozanimod treatment is effective at helping patients remain relapse-free and suggest that a majority of patients remain relapse-free for up to eight weeks after treatment is interrupted.” "These data presented at ACG demonstrate Zeposia treatment prevents disease relapse over one year of continuous treatment and maintains disease control even in the event of temporary interruption,” said Jonathan Sadeh, MD, MSc, senior vice president of Immunology and Fibrosis Development, Bristol Myers Squibb. “These analyses reinforce the established profile of Zeposia for people living with moderately to severely active UC and underscore our long-standing commitment to the gastroenterology community.” Additional analyses presented demonstrate no additional safety signals were observed after approximately two years of continuous Zeposia treatment. Bristol Myers Squibb thanks the patients and investigators involved in the True North study. Bristol Myers Squibb-sponsored abstracts featured at the ACG 2022 Scientific Meeting include: Duration of response to ozanimod after treatment withdrawal: Results from the Phase 3 True North study Author: Bruce E. Sands Presentation Number: 62 Plenary Session 4A – Colon/IBD Efficacy and safety of 2 years of continuous ozanimod treatment: Interim analysis of the True North open-label extension study Author: Maria T. Abreu Presentation Number: D0406 Poster Humoral immune responses to SARS-CoV-2 vaccines in an ozanimod open-label extension study Author: Freddy Caldera Presentation Number: E0367 Poster Efficacy of ozanimod in vedolizumab-exposed patients with ulcerative colitis: A Phase 3 True North post hoc analysis Author: Bruce E. Sands Presentation Number: B0352 Poster Zeposia Clinical Encore Presentations Ozanimod is an effective oral treatment for patients with ulcerative colitis regardless of moderate or severe endoscopic disease activity at baseline: A post hoc analysis of the Phase 3 True North study Author: Douglas C. Wolf Presentation Number: C0387 Poster Ozanimod is an effective oral treatment for patients with ulcerative colitis regardless of baseline endoscopic disease distribution: A post hoc analysis of the Phase 3 True North study Author: Anita Afzali Presentation Number: E0343 Poster Evaluation of ozanimod efficacy and safety in older patients with ulcerative colitis: Post hoc analysis from the Phase 3 True North study Author: Nabeel Khan Presentation Number: A0391 Poster Hepatic safety of ozanimod in ulcerative colitis and relapsing multiple sclerosis Phase 3 trials Author: David T. Rubin Presentation Number: B0368 Poster Ozanimod is an efficacious oral therapy after 5-ASA failure in immunomodulator- and biologic-naive patients with ulcerative colitis: Post hoc analysis from True North Author: Bruce E. Sands Presentation Number: A0392 Poster Association between absolute lymphocyte count and ozanimod efficacy/safety in patients with moderate/severe ulcerative colitis: Results from the Phase 3 True North study Author: Sarah Harris Presentation Number: E0354 Poster Impact of ozanimod on fecal calprotectin levels and the association with efficacy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 True North study Author: Sarah Harris Presentation Number: E0355 Poster About True North True North is a Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial assessing the efficacy and safety of Zeposia 0.92 mg in patients with moderately to severely active ulcerative colitis (UC) who had an inadequate response or were intolerant to any of the following: oral aminosalicylates, corticosteroids, immunomodulators or a biologic. Patients were to be receiving treatment with oral aminosalicylates and/or corticosteroids prior to and during the induction period. A total of 30% of patients had previously failed or were intolerant to tumor necrosis factor (TNF) blockers. Of these patients, 63% received at least two biologics including TNF blockers. At study entry, mean age was 42 years, 60% were male and mean disease duration was 7 years; patient characteristics were well balanced across treatment groups. In the 10-week induction study (UC Study 1), a total of 645 patients were randomized 2:1 to receive Zeposia (n=429) or placebo (n=216), of whom 94% and 89%, respectively, completed the induction study. No new safety signals were observed in the induction phase. In the maintenance study (UC Study 2) a total of 457 patients who received Zeposia in either UC Study 1 or in an open-label arm and achieved clinical response at Week 10 were re-randomized 1:1 and were treated with either Zeposia 0.92 mg (n=230) or placebo (n=227) for 42 weeks, for a total of 52 weeks of treatment. Concomitant aminosalicylates were required to remain stable through Week 52. Patients on concomitant corticosteroids were to taper their dose upon entering the maintenance study. Of these, 80% and 54.6% of patients who received Zeposia and placebo, respectively, completed the study. In the maintenance phase, the overall safety profile was consistent with the known safety profile for Zeposia and patients with moderate to severe UC. More information about the True North trial can be found on www.clinicaltrials.gov , NCT02435992. For the True North open-label extension (OLE) study, eligible patients who completed the maintenance UC Study 2 were rolled into the OLE study, which is ongoing and designed to assess the longer-term profile of Zeposia for the treatment of moderately to severely active UC. Patients were also eligible to enter the OLE study if they completed UC Study 1 and did not achieve a clinical response or if they experienced a disease relapse during UC Study 2. Among patients who entered the trial, clinical remission, clinical response, endoscopic improvement and symptomatic remission were generally maintained through Week 142. No new safety concerns were identified in this study extension in patients with ulcerative colitis. More information about the open-label extension trial can be found on https://www.clinicaltrials.gov/ , NCT02531126. About Ulcerative Colitis Ulcerative colitis, a chronic inflammatory bowel disease (IBD), is characterized by an irregular, chronic immune response that creates inflammation and ulcers (sores) in the mucosa (lining) of the large intestine (colon) or rectum. Symptoms include bloody stools, severe diarrhea and frequent abdominal pain. Ulcerative colitis has a major impact on patients' health-related quality of life, including physical functioning, social and emotional well-being and ability to go to work/school. Many patients have an inadequate response or do not respond at all to currently available therapies. It is estimated that approximately 12.6 million people worldwide are living with IBD. About Zeposia ( ozanimod ) Zeposia ( ozanimod) is an oral, sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1 and 5. Zeposia reduces the capacity of lymphocytes to migrate from lymphoid tissue, reducing the number of circulating lymphocytes in peripheral blood. The mechanism by which Zeposia exerts therapeutic effects in ulcerative colitis (UC) is unknown but may involve the reduction of lymphocyte migration into the intestines. Bristol Myers Squibb is continuing to evaluate Zeposia in the ongoing True North open-label extension trial, designed to assess the longer-term profile of Zeposia for the treatment of moderately to severely active UC. The company is also investigating Zeposia for the treatment of moderately to severely active Crohn’s disease in the ongoing Phase 3 YELLOWSTONE clinical trial program. The U.S. Food and Drug Administration approved Zeposia for the treatment of adults with relapsing forms of multiple sclerosis in March 2020 and adults with moderately to severely active UC in May 2021. The European Commission approved Zeposia for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease as defined by clinical or imaging features in May 2020 and for the treatment of adults with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent in November 2021. U.S. FDA APPROVED INDICATIONS ZEPOSIA ® (ozanimod) is indicated for the treatment of: 1. Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. 2. Moderately to severely active ulcerative colitis (UC) in adults. IMPORTANT SAFETY INFORMATION Contraindications: Patients who in the last 6 months, experienced myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), decompensated heart failure requiring hospitalization, or Class III/IV heart failure or have a presence of Mobitz type II second-degree or third-degree atrioventricular (AV) block, sick sinus syndrome, or sino-atrial block, unless the patient has a functioning pacemaker Patients with severe untreated sleep apnea Patients taking a monoamine oxidase (MAO) inhibitor Infections : ZEPOSIA may increase the susceptibility to infections. Life-threatening and rare fatal infections have occurred in patients receiving ZEPOSIA. Obtain a recent (i.e., within 6 months or after discontinuation of prior MS or UC therapy) complete blood count (CBC) including lymphocyte count before initiation of ZEPOSIA. Delay initiation of ZEPOSIA in patients with an active infection until the infection is resolved. Consider interruption of treatment with ZEPOSIA if a patient develops a serious infection. Continue monitoring for infections up to 3 months after discontinuing ZEPOSIA. Herpes zoster was reported as an adverse reaction in ZEPOSIA-treated patients. Herpes simplex encephalitis and varicella zoster meningitis have been reported with sphingosine 1-phosphate (S1P) receptor modulators. Patients without a healthcare professional-confirmed history of varicella (chickenpox), or without documentation of a full course of vaccination against varicella zoster virus (VZV), should be tested for antibodies to VZV before initiating ZEPOSIA. A full course of vaccination for antibody-negative patients with varicella vaccine is recommended prior to commencing treatment with ZEPOSIA. Cases of fatal cryptococcal meningitis (CM) were reported in patients treated with another S1P receptor modulator. If CM is suspected, ZEPOSIA should be suspended until cryptococcal infection has been excluded. If CM is diagnosed, appropriate treatment should be initiated. In the MS and UC clinical studies, patients who received ZEPOSIA were not to receive concomitant treatment with antineoplastic, non-corticosteroid immunosuppressive, or immune-modulating therapies used for treatment of MS and UC. Concomitant use of ZEPOSIA with any of these therapies would be expected to increase the risk of immunosuppression. When switching to ZEPOSIA from immunosuppressive medications, consider the duration of their effects and their mode of action to avoid unintended additive immunosuppressive effects. Use of live attenuated vaccines should be avoided during and for 3 months after treatment with ZEPOSIA. If live attenuated vaccine immunizations are required, administer at least 1 month prior to initiation of ZEPOSIA. Progressive Multifocal Leukoencephalopathy (PML) : PML is an opportunistic viral infection of the brain that typically occurs in patients who are immunocompromised, and that usually leads to death or severe disability. PML has been reported in patients treated with S1P receptor modulators, including ZEPOSIA, and other MS and UC therapies and has been associated with some risk factors. If PML is suspected, withhold ZEPOSIA and perform an appropriate diagnostic evaluation. If confirmed, treatment with ZEPOSIA should be discontinued. Bradyarrhythmia and Atrioventricular Conduction Delays : Since initiation of ZEPOSIA may result in a transient decrease in heart rate and atrioventricular conduction delays, dose titration is recommended to help reduce cardiac effects. Initiation of ZEPOSIA without dose escalation may result in greater decreases in heart rate. If treatment with ZEPOSIA is considered, advice from a cardiologist should be sought for those individuals: with significant QT prolongation with arrhythmias requiring treatment with Class 1a or III anti-arrhythmic drugs with ischemic heart disease, heart failure, history of cardiac arrest or myocardial infarction, cerebrovascular disease, and uncontrolled hypertension with a history of Mobitz type II second-degree or higher AV block, sick sinus syndrome, or sino-atrial heart block Liver Injury : Elevations of aminotransferases may occur in patients receiving ZEPOSIA. Obtain liver function tests, if not recently available (i.e., within 6 months), before initiation of ZEPOSIA. Patients who develop symptoms suggestive of hepatic dysfunction should have hepatic enzymes checked and ZEPOSIA should be discontinued if significant liver injury is confirmed. Caution should be exercised when using ZEPOSIA in patients with history of significant liver disease. Fetal Risk : There are no adequate and well-controlled studies in pregnant women. Based on animal studies, ZEPOSIA may cause fetal harm. Women of childbearing potential should use effective contraception to avoid pregnancy during treatment and for 3 months after stopping ZEPOSIA. Women who become pregnant while taking ZEPOSIA for MS may enroll in the ZEPOSIA pregnancy registry by calling 1-877-301-9314 or visiting www.zeposiapregnancyregistry.com . Increased Blood Pressure : Increase in systolic pressure was observed after about 3 months of treatment and persisted throughout treatment. Blood pressure should be monitored during treatment and managed appropriately. Certain foods that may contain very high amounts of tyramine could cause severe hypertension in patients taking ZEPOSIA. Patients should be advised to avoid foods containing a very large amount of tyramine while taking ZEPOSIA. Respiratory Effects : ZEPOSIA may cause a decline in pulmonary function. Spirometric evaluation of respiratory function should be performed during therapy, if clinically indicated. Macular Edema : S1P modulators have been associated with an increased risk of macular edema. Patients with a history of uveitis or diabetes mellitus are at increased risk. Patients with a history of these conditions should have an ophthalmic evaluation of the fundus, including the macula, prior to treatment initiation and regular follow-up examinations. An ophthalmic evaluation is recommended in all patients at any time if there is a change in vision. Continued use of ZEPOSIA in patients with macular edema has not been evaluated; potential benefits and risks for the individual patient should be considered if deciding whether ZEPOSIA should be discontinued. Posterior Reversible Encephalopathy Syndrome (PRES) : Rare cases of PRES have been reported in patients receiving a S1P receptor modulator. If a ZEPOSIA-treated patient develops unexpected neurological or psychiatric symptoms or any symptom/sign suggestive of an increase in intracranial pressure, a complete physical and neurological examination should be conducted. Symptoms of PRES are usually reversible but may evolve into ischemic stroke or cerebral hemorrhage. Delay in diagnosis and treatment may lead to permanent neurological sequelae. If PRES is suspected, treatment with ZEPOSIA should be discontinued. Unintended Additive Immunosuppressive Effects From Prior Immunosuppressive or Immune-Modulating Drugs : When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation. Initiating treatment with ZEPOSIA after treatment with alemtuzumab is not recommended. Severe Increase in Multiple Sclerosis (MS) Disability After Stopping ZEPOSIA : In MS, severe exacerbation of disease, including disease rebound, has been rarely reported after discontinuation of a S1P receptor modulator. The possibility of severe exacerbation of disease should be considered after stopping ZEPOSIA treatment so patients should be monitored upon discontinuation. Immune System Effects After Stopping ZEPOSIA : After discontinuing ZEPOSIA, the median time for lymphocyte counts to return to the normal range was 30 days with approximately 90% of patients in the normal range within 3 months. Use of immunosuppressants within this period may lead to an additive effect on the immune system, therefore caution should be applied when initiating other drugs 4 weeks after the last dose of ZEPOSIA. Most Common Adverse Reactions that occurred in the MS clinical trials of ZEPOSIA-treated patients (≥ 4%): upper respiratory infection, hepatic transaminase elevation, orthostatic hypotension, urinary tract infection, back pain, and hypertension. In the UC clinical trials, the most common adverse reactions that occurred in ≥4% of ZEPOSIA-treated patients and greater than in patients who received placebo were upper respiratory infection, liver test increased, and headache. Use in Specific Populations : Hepatic Impairment: Use is not recommended. For additional safety information, please see the full Prescribing Information and Medication Guide . Bristol Myers Squibb: Pioneering Paths Forward in Immunology to Transform Patients’ Lives Bristol Myers Squibb is inspired by a single vision – transforming patients’ lives through science. For people living with immune-mediated diseases, the debilitating reality of enduring chronic symptoms and disease progression can take a toll on their physical, emotional and social well-being, making simple tasks and daily life a challenge. Driven by our deep understanding of the immune system that spans over 20 years of experience, and our passion to help patients, the company continues to pursue pathbreaking science with the goal of delivering meaningful solutions that address unmet needs in rheumatology, gastroenterology, dermatology and neurology. We follow the science, aiming to tailor therapies to individual needs, improve outcomes and expand treatment options by working to identify mechanisms with the potential to achieve long-term remission – and perhaps even cures – in the future. By building partnerships with researchers, patients and caregivers to deliver innovative treatments, Bristol Myers Squibb strives to elevate patient care to new standards and deliver what matters most – the promise of living a better life. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook and Instagram . Cautionary Statement Regarding Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, that future post-marketing studies may not be consistent with the results of this study, that Zeposia , for the indication described in this release, may not be commercially successful, that any marketing approvals, if granted, may have significant limitations on their use, and that continued approval of such product candidate for such indication described in this release may be contingent upon verification and description of clinical benefit in additional confirmatory trials. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2021, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise. corporatefinancial-news Bristol Myers Squibb Media Inquiries: media@bms.com Investors: Tim Power 609-252-7509 timothy.power@bms.com Nina Goworek 908-673-9711 nina.goworek@bms.com Source: Bristol Myers Squibb

Rise in cancer cases globally is resulting into revenue-generation opportunities in the cancer immunotherapy market Presence of sturdy healthcare infrastructure and sizable number of cancer patients drives the North America market ALBANY, N.Y. , June 27, 2022 /PRNewswire/ -- As per the cancer immunotherapy market statistics provided by Transparency Market Research (TMR), the global market is projected to be valued at more than US$ 261.7 Bn by 2031. Moreover, the global market study on cancer immunotherapy notes that market is expected to expand at a CAGR of 13.6% during the forecast period, from 2022 to 2031. The report by TMR offers in-depth knowledge on different factors influencing the growth of the cancer immunotherapy market. Hence, readers are enlightened on key factors including the growth drivers, investment opportunities, challenges, and ongoing trends of the cancer immunotherapy market. Players in the cancer immunotherapy market are investing heavily in the R&D projects, which are focused on the development of innovative and effective products. This factor is fueling the expansion of the global market, notes the cancer immunotherapy market outlook by TMR. Request Brochure of Cancer Immunotherapy Market Research Report – Cancer Immunotherapy Market: Key Findings Over the period of past few years, there has been a rise in the number of people suffering from different cancer types such as prostate cancer, blood cancer, breast cancer, melanoma, colorectal cancer, lung cancer, and other minor cancer types. Rise in the prevalence of breast cancer globally is leading to increased need for immunotherapy. This aside, surge in the overall air pollution levels in metropolitan cities and rise in population of smokers across the globe are resulting into increased number of lung cancer patients globally. This factor, in turn, is generating profitable prospects in the global cancer immunotherapy market, according to analysts at TMR. Immune checkpoint inhibitors, immune system modulators, and monoclonal antibodies are some of the therapy types available in the global cancer immunotherapy market. Among all, monoclonal antibodies is one of the popular treatment techniques increasingly adopted in the healthcare industry owing to its cost-efficient nature over other therapy options, notes a TMR study on the global cancer immunotherapy market. Request for Analysis of COVID-19 Impact on Cancer Immunotherapy Market – Cancer Immunotherapy Market: Growth Boosters Increase in inclination among patients and healthcare professionals toward the use of the target therapy instead of standard options is fueling the sales growth in the market Surge in the prevalence of cancer globally is driving sales growth in the cancer immunotherapy market Rise in the adoption of the cancer immunotherapy treatment by patients owing to its cost-effective nature as well as lesser side effects is boosting the sales growth in the market Get Exclusive PDF Sample Copy of Cancer Immunotherapy Market Report – Cancer Immunotherapy Market: Regional Analysis The cancer immunotherapy market is estimated to attract notable business opportunities in North America during the forecast period. This growth is ascribed to many factors including the presence of well-developed healthcare infrastructure, increase in number of cancer patients, rise in adoption of immunotherapy, and expansion of bioinformatics tools that help in advancing the drug development process. The cancer immunotherapy market in Asia Pacific is prognosticated to expand at rapid pace during the forecast period owing to rise in the number of clinical trials intended for new cancer treatment drugs and increase in the number of FDA approvals for novel treatment drugs in many regional nations. Make an Enquiry Before Buying – Cancer Immunotherapy Market: Key Players Some of the key players profiled in the report are: Bristol-Myers Squibb Company Amgen, Inc. GlaxoSmithKline plc AstraZeneca plc F. Hoffmann-La Roche Ltd. Eli Lilly and Company Janssen Biotech, Inc. Sanofi Pfizer, Inc. Merck & Co., Inc. Novartis AG Spectrum Pharmaceuticals, Inc. Takeda Pharmaceuticals Cancer Immunotherapy Market Segmentation Therapy Type Monoclonal Antibodies Immune Checkpoint Inhibitors PD-1/PD-L1 CTLA-4 Immune System Modulators Cancer Vaccines Others Therapeutic Area Lung Cancer Colorectal Cancer Breast Cancer Prostate Cancer Melanoma Blood Cancers Others End-user Hospitals Ambulatory Surgical Centers (ASCs) Cancer Research Centers Clinics Regions Covered North America Latin America Europe Latin America Middle East & Africa Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated with Healthcare Industry Reports by Transparency Market Research: Oncolytic Virus Immunotherapy Market: The oncolytic virus immunotherapy is anticipated to revolutionize the future of cancer treatment. A number of oncolytic virus immunotherapies are in the development phase and likely to hit the oncolytic virus immunotherapy market over the course of the forecast period. Allergy Immunotherapy Market: Expansion of the global allergy immunotherapy market is attributed to the rise in awareness regarding allergy treatment, rapidly growing allergic population, and launch of new products. Anticancer Drugs Market: The increasing number of deaths caused due to cancer is a prime factor augmenting the growth of the global anticancer drugs market. Cancer is a gathering of sicknesses related with strange cell development with the possibility to torment or spread to different pieces of the body. Head and Neck Cancer Market: The global head and neck cancer market is driven by increase in the patient population, rise in health care infrastructure in developing economies, growth of the pharmaceutical industry, surge in research and development activity, increase in product approvals, and rise in government initiatives. Prostate Cancer Therapeutics Market: The movement of the prostate cancer therapeutics market, however, could be hampered, in light of the reluctance evinced by patients towards premium cancer therapies and drugs. Breast Cancer Diagnostics Market: High prevalence and increase in incidence rate of breast cancer across the globe and technological advancements in diagnostic techniques are anticipated to fuel the growth of the global breast cancer diagnostics market. Cancer Diagnostics Market: Increasing trend for preventive diagnosis due to escalating prevalence continues, early diagnosis enables better clinical and economical outcomes for patients are projected to drive the global cancer diagnostics market during the forecast period. Hyperthermia Cancer Treatment Market: High intensity focused ultrasound (HIFU), nanoparticle heating, and scanned focused ultrasound (SFUS) techniques are broadening revenue streams for companies in the hyperthermia cancer treatment market. About Us Transparency Market Research is a global market intelligence company providing market research reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - Contact Us: Rohit Bhisey Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Website: Blog: Email: [email protected] SOURCE Transparency Market Research

NEW YORK, June 21, 2022 /PRNewswire/ -- As per Zion Market Research study, The global hematology analyzers and reagents market was worth around USD 8.1 billion in 2021 and is estimated to grow to about USD 19.5 billion by 2028, with a compound annual growth rate (CAGR) of approximately 7.1 percent over the forecast period. Key Industry Insights & Finding of the Hematology Analyzers and Reagents Market Reports: As per the analysis shared by our research analyst, the Hematology Analyzers and Reagents Market is expected to grow annually at a CAGR of around 7.1 % (2022-2028). Through the primary research, it was established that the Hematology Analyzers and Reagents Market was valued approximately USD 8.1 Billion in 2021 and is projected to reach to roughly USD 19.5 Billion by 2028. North America is expected to dominate the global hematology analyzers and reagents market owing to the strong presence of key companies and rising investment to create innovative and more accurate result-generating medical equipment. Europe is expected to take the lead due to a rise in the number of diagnostic clinics and increased awareness of hematological illnesses in the region. Rising frequency of hematological illnesses among the patient population, the worldwide hematology analyzers and reagent market opportunity is expected to be greatest in the undeveloped areas of Asia Pacific and Latin America. Zion Market Research published the latest report titled as "Hematology Analyzers And Reagents Market By Product Type (Instruments And Reagents), By Application (Hemorrhagic Conditions, Blood Cancers, Anemias Immune System-Related Conditions, Infection-Related Conditions, And Others) By End User (Diagnostic Laboratories, Hospitals & Clinics, Research Institutes, And Others), And By Region – Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2022 – 2028." into their research database. Hematology Analyzers and Reagents Market : Overview Hematology is a field of medicine that deals with the diagnosis, research, treatment, and prevention of blood diseases. Hematology analyzers are equipment that performs tests on blood samples. They're used to do tests like a full blood count, which includes platelet, white, red, and hemoglobin counts, as well as to characterize blood cells to detect a medical condition. Get a Free Sample Report with All Related Graphs & Charts (with COVID 19 Impact Analysis): Our Free Sample Report Includes: 2022 Updated Report Introduction, Overview, and In-depth industry analysis COVID-19 Pandemic Outbreak Impact Analysis Included 190 + Pages Research Report (Inclusion of Updated Research) Provide Chapter-wise guidance on Request 2022 Updated Regional Analysis with Graphical Representation of Size, Share & Trends Includes Updated List of tables & figures Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis Zion Market Research methodology Industry Dynamics: Hematology Analyzers and Reagents Market : Growth Drivers Growing incidence of blood disorders is predicted to drive the market growth. Red blood cell disorders including anemia, bleeding (platelet) disorders, and white blood cell disorders are all characterized by benign blood diseases. Other blood disorders, such as lymphoma, leukemia, and sickle cell anemia can cause chronic sickness or even death. Sickle cell disease, the most prevalent form of a hereditary blood ailment, affects between 70,000 to 100,000 people in the United States. Further, annually, approximately 1.24 million instances of blood cancer are diagnosed globally, accounting for around 6% of all cases of cancer. Owing to such a huge burden of the disease, the need for blood tests is rising, thereby leading to an increase in demand for hematology analyzers and reagents. In addition to this, advantageous reimbursement policies, rise in spending on health, and developing healthcare infrastructure in developing countries are some of the major factors that are fostering the growth of the global hematology analyzers and reagents market. Furthermore, an increase in blood donation & blood transfusion rate is also booming the market. Hematology Analyzers and Reagents Market : Restraints High costs associated with the hematology analyzers may hinder the market growth. Hematology analyzers and reagents are medical products and commodities that are used to identify and count individual blood cells in a time-efficient manner. This equipment has replaced the traditional methods of counting blood cells one by one under a magnification, which was formerly provided by research laboratory professionals. Hematology analyzer reagents are scientific, automatic, rapid, and provide greater accuracy in analysis. Flow cytometry is the most advanced and costly approach currently available. All such factors are likely to impede the growth of the market. In addition to this, hematology analyzers require high maintenance costs which may also hinder the market growth. Moreover, less developed healthcare infrastructure and a dearth of skilled professionals to operate the hematology analyzer are also some of the restraining factors of the market. Directly Purchase a Copy of the Report @ Global Hematology Analyzers and Reagents Market : Opportunities Advanced technology in the field of medical equipment may generate numerous opportunities for the market growth. Some of the important factors are increasing usage of automated hematology equipment, growing technical breakthroughs, and integration of fundamental flow-cytometry techniques in advanced hematology analyzers may lead to beneficial opportunities for the growth of the global hematology analyzer & reagent market during the forecast period. Further, the advent of digital imaging systems in hematological laboratories and the use of microfluidics technology in hematology analyzers might offer up new potential for new market players. Furthermore, heavy investments by the big players for new product launches and the presence of strong distribution chains may also drive market growth in the forecast period. Global Hematology Analyzers and Reagents Market : Challenges Quality of the hematology analyzers might be a challenge for the market growth. The phenomenon of a cell count that is too high or too few can also be caused by an automatic blood cell analyzer. Some analyzers, particularly impedance type counters, may not be able to discriminate between nucleated red blood cells and microscopic platelet aggregation since they only assess the size and quantity of particles. Platelet aggregation can be mistaken for red blood cells or white blood cells, and nucleated red blood cells can be mistaken for white blood cells as well. Lymphocytes are particularly sensitive. Atypical cells that are big or unreadable, immature neutrophils, and toxic reactive lymphocytes are also prone to be misclassified. The major threats include incorrect findings, which might lead to therapy delays or improper treatment. Thus, the quality issues of the hematology analyzers may act as a major challenge for the market growth. Global Hematology Analyzers and Reagents Market : Segmentation The global hematology analyzers and reagents market is classified into product type, application, end-user, and region. Based on the product type, the global market is split into reagents and instruments. The application segment consists of hemorrhagic conditions, blood cancers, anemias immune system-related conditions, infection-related conditions, and others. By end-user, the market is bifurcated into research institutes, hospitals & clinics, diagnostic laboratories, and others. Get More Insight before [email protected] : List of Key Players of Hematology Analyzers and Reagents Market : Abbott Siemens Nihon Kohden Danaher Corporation Sysmex Corporation Roche BioSystems Bio-Rad Laboratories HORIBA Boule Diagnostics Key questions answered in this report: What are the growth rate forecast and market size for Hematology Analyzers and Reagents Market ? What are the key driving factors propelling the Hematology Analyzers and Reagents Market forward? What are the most important companies in the Hematology Analyzers and Reagents Market Industry? What segments does the Hematology Analyzers and Reagents Market cover? How can I receive a free copy of the Hematology Analyzers and Reagents Market sample report and company profiles? Report Scope: Free Brochure: Recent Developments In April 2022, Sysmex Europe, launched the XQ-320, a three-part differential automated hematology analyzer. The XQ-320 is a reliable instrument that requires little sample volume, bench space, or maintenance. In July 2021, PixCell Medical, a pioneer in point-of-care diagnostics, revealed that it has entered a new distribution deal with Gamidor Diagnostics to market PixCell's hematology analyzer, HemoScreen™, all over Israel. In January 2021, Roche has renewed a long-standing collaboration with Sysmex to market Sysmex hematological diagnostic products, including instruments and reagents, under a new worldwide commercial partnership agreement. Regional Dominance: North America is projected to dominate the market for hematology analyzers and reagents. North America is expected to dominate the global hematology analyzers and reagents market owing to the strong presence of key companies and rising investment to create innovative and more accurate result-generating medical equipment. Europe is expected to take the lead due to a rise in the number of diagnostic clinics and increased awareness of hematological illnesses in the region. On the other hand, because of the rising frequency of hematological illnesses among the patient population, the worldwide hematology analyzers and reagent market opportunity is expected to be greatest in the undeveloped areas of Asia Pacific and Latin America. Global Hematology Analyzers and Reagents Market is segmented as follows: Hematology Analyzers and Reagents Market : By Product Type Outlook (2022-2028) Instruments Reagents Hematology Analyzers and Reagents Market : By Application Outlook (2022-2028) Hemorrhagic Conditions Blood Cancers Anemias Immune System Related Conditions Infection Related Conditions Others Hematology Analyzers and Reagents Market : By End Use Outlook (2022-2028) Diagnostic laboratories Hospitals & Clinics Research institutes Others Hematology Analyzers and Reagents Market : By Region Outlook (2022-2028) North America The U.S. Canada Europe France The UK Spain Germany Italy Rest of Europe Asia Pacific China Japan India South Korea Southeast Asia Rest of Asia Pacific Latin America Brazil Mexico Rest of Latin America Middle East & Africa GCC South Africa Rest of Middle East & Africa Press Release For Hematology Analyzers and Reagents Market : Browse Other Related Research Reports from Zion Market Research Bone Growth Stimulators Market - Global Industry Analysis : The global bone growth stimulators market was worth around USD 1.21 billion in 2021 and is estimated to grow to about USD 1.85 billion by 2028, with a compound annual growth rate (CAGR) of approximately 5.2 percent over the forecast period. Women's Health Rehabilitation Products Market - Global Industry Analysis : The global Women's Health Rehabilitation Products Market accrued earnings worth approximately 3.30 (USD Billion) in 2021 and is predicted to gain revenue of about 9.14 (USD Billion) by 2028, is set to record a CAGR of nearly 5.1% over the period from 2022 to 2028. Digital Patient Monitoring Devices Market - Global Industry Analysis : The global Digital Patient Monitoring Devices Market accrued earnings worth approximately 63.1 (USD Billion) in 2020 and is predicted to gain revenue of about 447.3(USD Billion) by 2028, is set to record a CAGR of nearly 24.1% over the period from 2021 to 2028. Browse through Zion Market Research's coverage of the Global Medical Device Industry Follow Us on: LinkedIn | Twitter | Facebook About Us Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client's needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us . Contact Us: Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States Tel: +49-322 210 92714 USA/Canada Toll Free No.1-855-465-4651 Email: [email protected] Website: Blog - | Market Business Insights Logo: SOURCE Zion Market Research